Podcast Episodes
Back to Search
London based Laverock shows BiotechTV the new space it moved into in LBIC's Apex Building in Kings Cross where it will be doing its work on programmable gene silencing
CEO David Venables describes Laverock's platform that repurposed miRNA to reprogram cells in a highly specific way. It's own lead programs will be in…
1 year, 4 months ago
The London BioScience Innovation Centre (LBIC) today launched its new Apex Building lab space facility for biotech companies in the heart of the Kings Cross Knowledge Quarter
Dr. Rich Ferrie gives BiotechTV a preview of the new facilities and describes how it is aimed for growing companies that have already achieved a seri…
1 year, 4 months ago
Talking chromatin regulation at Foghorn Therapeutics - whose partner Lilly will have preclinical data at AACR highlighting how the lead SMARCA2 program could do in combinations with other therapies
CEO Adrian Gottschalk describes chromatin regulation at a high level, and walks us through the Lilly partnership targeting SMARCA2, and Foghorn's ind…
1 year, 4 months ago
Epicrispr Biotechnologies' CEO Amber Salzman describes how her company will be utilizing AI muscle analysis in its clinical study for facioscapulohumeral muscular dystrophy
She describes why such an analysis would be beneficial in analyzing clinical benefit for this type of condition - where the patient population is het…
1 year, 4 months ago
Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on ACM, and more
He describes the clinical data in FA cardiomyopathy that was announced this month, and explains how the company is preparing to begin a clinical tria…
1 year, 4 months ago
Metsera's CEO Whit Bernard on the obesity space, including GLP-1s, amylin analogs, and how the company is also developing both as oral peptides
He describes how Metsera, which had its IPO two months ago, is aiming to develop a differentiated GLP-1 vs currently marketed products by having a lo…
1 year, 4 months ago
On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73
He describes the market potential of the company's HIF-2⍺, a target that has already been de-risked by a large pharma, why he believes being Fc silen…
1 year, 4 months ago
As federal funding for cancer research has been jeopardized at NIH and academia, Parker Institute for Cancer Immunotherapy is one private institution ready to step up and broaden its impact
CSO John Connolly describes how recent new hires and a willingness to lead will expand PICI's already broad reach in cancer research circles. Plus, h…
1 year, 5 months ago
Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies
Founder and CEO Nicole Paulk describes the process, which allows the public to invest as little as $100, and why she views the investors that come wi…
1 year, 5 months ago
Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)
CEO Rick Winningham describes the science behind ampreloxetine, and the rationale for developing it for patients with multiple system atrophy. A comm…
1 year, 5 months ago